EUVIMEDEUVIMED entdecken
VergleichsstudieOpen Access · CC BY 4.0

Comparative Effectiveness of Direct Oral Anticoagulants and Warfarin on Venous Thromboembolism in Cancer Patients

Hye-In Jung iD, Claudia Geue, Giorgio Ciminata, Eui-Kyung Lee iD

Cancer Medicine · 2025

DOI: 10.1002/cam4.71209 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Cancer Medicine, 2025. Verfasst von Hye-In Jung und 3 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy, Sungkyunkwan University, Suwon, South Korea. Hauptthemen laut MEDLINE: Venous Thromboembolism, Warfarin, Neoplasms, Anticoagulants. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Korea Health Industry Development Institute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Venous thromboembolism (VTE) is a leading cause of mortality in cancer patients, and a substantial number of patients are being treated with oral anticoagulants. We aim to assess the comparative effectiveness of direct oral anticoagulants (DOACs) compared to warfarin for VTE treatment in cancer patients.

Methods

In this retrospective cohort study, we included 2,367 cancer patients who are new users of oral anticoagulants (OACs) for VTE treatment from 2009 to 2021 in NHS Scotland. Patients were grouped by OAC type, DOACs or warfarin. To adjust for confounding, inverse probability treatment weighting was applied. Outcomes included mortality, VTE recurrence, and major bleeding. We calculated Hazard Ratio (HR) using Cox regression and sub‐distribution HR (sHR) using a competing risk framework (Fine and Gray method) for VTE recurrence and major bleeding. Subgroup analyses were conducted for individual DOACs.

Results

Patients on DOACs had lower risks of VTE recurrence (sHR 0.73 95% CI 0.59–0.90) and major bleeding (sHR 0.68, 95% CI 0.53–0.88) compared to patients on warfarin. Patients on rivaroxaban (HR 1.21, 95% CI 1.04–1.39) and edoxaban (HR 1.59, 95% CI 1.15–2.22) had a significantly higher risk of mortality, while a comparable risk of mortality was observed (HR 0.91, 95% CI 0.76–1.08) for patients on apixaban compared to patients on warfarin.

Conclusion

This study provides insight into the effectiveness of DOACs compared to warfarin for VTE in cancer patients. Patients on DOACs had lower risks of VTE recurrence and major bleeding. We suggest healthcare professionals consider the potential benefits of individual DOACs when making treatment decisions.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Venous ThromboembolismWarfarinNeoplasmsAnticoagulantsFactor Xa InhibitorsHumansFemaleMaleRetrospective StudiesAgedMiddle AgedAdministration, OralHemorrhageRivaroxabanScotlandRecurrencePyridonesAged, 80 and overTreatment OutcomePyrazolesPyridinesThiazoles

Stichwörter der Autor:innen

anticoagulantsneoplasmsvenous thromboembolism

Substanzen

WarfarinAnticoagulantsRivaroxabanedoxabanFactor Xa InhibitorsapixabanPyridonesPyrazolesPyridinesThiazoles

Autor:innen und Institutionen

  • School of Pharmacy, Sungkyunkwan University, Suwon, South Korea.
  • Health Economics and Health Technology Assessment (HEHTA), University of Glasgow, Glasgow, UK.

ORCID-Profile: Hye-In Jung, Eui-Kyung Lee

Förderung

  • Korea Health Industry Development Institute

Zitieren

APA

Jung, H. I., Geue, C., Ciminata, G., & Lee, E. K. (2025). Comparative Effectiveness of Direct Oral Anticoagulants and Warfarin on Venous Thromboembolism in Cancer Patients. Cancer Medicine. https://doi.org/10.1002/cam4.71209

Vancouver

Jung HI, Geue C, Ciminata G, Lee EK. Comparative Effectiveness of Direct Oral Anticoagulants and Warfarin on Venous Thromboembolism in Cancer Patients. Cancer Medicine. 2025. doi:10.1002/cam4.71209

BibTeX
@article{Jung2025,
  author = {Jung, Hye-In and Geue, Claudia and Ciminata, Giorgio and Lee, Eui-Kyung},
  title = {Comparative Effectiveness of Direct Oral Anticoagulants and Warfarin on Venous Thromboembolism in Cancer Patients},
  journal = {Cancer Medicine},
  year = {2025},
  doi = {10.1002/cam4.71209}
}
Kostenlos starten →